Abstract
Myasthenia gravis (MG) is an autoimmune condition related to autoantibodies against certain proteins in the postsynaptic membranes in the neuromuscular junction. This disorder has a multifactorial inheritance. The connection between environmental and genetic factors can be established by epigenetic factors, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). XLOC_003810, SNHG16, IFNG-AS1, and MALAT-1 are among the lncRNAs with a possible role in the pathoetiology of MG. Moreover, miR-150-5p, miR-155, miR-146a-5p, miR-20b, miR-21-5p, miR-126, let-7a-5p, and let-7f-5p are among miRNAs whose roles in the pathogenesis of MG has been assessed. In the current review, we summarize the impact of miRNAs and lncRNAs in the development or progression of MG.
1. Introduction
Myasthenia gravis (MG) is an autoimmune condition caused by the presence of autoantibodies against certain proteins in the postsynaptic membranes in the neuromuscular junction [1]. The main detected autoantibodies are targeted against the muscle acetylcholine receptor (AChR) [2]. Other targets of autoantibodies are MuSK [3] and LRP4 [4]. The observed 35% concordance rate in MG occurrence among monozygotic twins shows the impact of environmental factors in the pathoetiology of this disorder [5]. From a clinical point of view, MG is characterized by fluctuating fatigability and weakness in a number of muscles, such as ocular, bulbar, and limb muscles. MG subtypes include ocular myasthenia and generalized myasthenia, which can have mild, moderate, or severe presentations [6]. Genetic studies have revealed the role of HLA loci as well as a number of other genes such as TNIP1 and PTPN22 in the pathogenesis of MG [5]. Moreover, pathways regulating differentiation of regulatory T cells as well as NF-κB signaling are implicated in this disorder. Significant heterogeneity has been detected in the course of MG in terms of epitopes targeted by autoantibodies, age of disease onset, and thymus histopathology [7]. While early onset MG cases are predominantly females with hyperplastic thymus histology, late onset cases are mainly males having normal or atrophic thymus [8].
Taken together, MG is a multifactorial disorder with both genetic and environmental etiologies. Meanwhile, the connection between environmental and genetic factors can be established by epigenetic factors [5], such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). In the current review, we summarize the impact of miRNAs and lncRNAs in the development or progression of MG.
2. LncRNAs and MG
LncRNAs are transcripts with sizes ranging from two hundred nucleotides to thousands of nucleotides. While they share several features with mRNAs, they lack the ability to be served as templates for proteins. Instead, they regulate expression of protein-coding genes at different levels [9]. Dysregulation of lncRNAs have been reported in MG. For instance, experiments in thymus specimens of patients with MG and MG-thymoma (MG-T) have shown upregulation of XLOC_003810 lncRNAs in these patients parallel with increased frequency of CD4+ T cells and release of proinflammatory cytokines in these patients. Functionally, XLOC_003810 upregulation has enhanced frequency of CD4+ T cells, increased synthesis of inflammatory cytokines, and reduced CD4+ PD-1+ T cells and CD14+ PD-L1+ monocytes in the mononuclear cells of thymus. XLOC_003810 silencing has resulted in opposite effects. Cumulatively, XLOC_003810 is an lncRNA that enhances T cells activation and suppresses PD-1/PD-L1 signaling in MG-T patients [10]. Another study has shown higher levels of XLOC_003810 in thymic CD4+ T cells obtained from MG-T patients compared with the control group. Additionally, MG-T thymic CD4+ T cells have exhibited a higher Th17/Treg ratio, higher frequency of Th17 cells and increased expression of Th17-associated proteins, while exhibiting lower amounts of Treg cells and downregulation of Treg-associated proteins. Notably, upregulation of XLOC_003810 has aggravated the imbalance between Th17 and Treg cells in MG-T thymic CD4+ T cells. Thus, XLOC_003810 could influence the balance between Th17 and Treg cells in the context of MG-T [11].
SNHG16 is another lncRNA that partakes in the pathogenesis of MG. This lncRNA acts as a competing endogenous RNA (ceRNA). Expression of SNHG16 has been found to be increased in peripheral blood mononuclear cells (PBMCs) of MG cases compared with controls. Mechanistically, SNHG16 increases expression of IL-10 through acting as a ceRNA for let-7c-5p. Moreover, SNHG16 could inhibit apoptotic processes in Jurkat cells and increase their proliferation through sponging this miRNA [12].
In MG patients, IFNG-AS1 is another dysregulated lncRNA whose expression is associated with the specific quantitative scoring system for MG, i.e., QMG as well as the presence of anti-AchR Ab antibody. Experiments in an animal model of MG have shown that this lncRNA affects proliferation of Th1/Treg cells and regulates expression of Th1/Treg-related transcription factors. Moreover, IFNG-AS1 has been found to decrease expressions of HLA-DRB and HLA-DOB. Moreover, it can affect the expression of CD40L and activity of CD4+ T cells through influencing HLA-DRB1 expression. Thus, IFNG-AS1 has a possible role in regulation of CD4+ T cell-associated immune response in MG [13].
Another study has reported downregulation of MALAT-1 in MG. This lncRNA has been found to compete with MSL2 for binding to miR-338-3p. Thus, MALAT-1/miR-338-3p/MSL2 axis is a new interaction network in MG [14].
A high throughput study in MG has shown upregulation of more than 1500 lncRNAs and downregulation of more than 1000 lncRNAs, parallel with dysregulation of several mRNAs in these patients. Dysregulated genes have been involved in MG-related cellular processes such as nucleic acid transcription factor activity, inflammatory responses, leukocytes activation, and lymphocytes proliferation. Moreover, they have been enriched in pathways related to immune function such as cytokine–cytokine receptor interaction, intestinal immune network for IgA synthesis, NOD-like receptor signaling, and cell adhesion, as well as NF-κB and TNF signaling pathways [15].
Another high throughput study has revealed differential expression of several lncRNAs in MG patients versus MG-T patients—among them has been lncRNA oebiotech_11933, whose dysregulation has been confirmed by real-time PCR. Cell responses to IFN-γ, platelet degranulation, chemokine receptor binding, and cytokine interactions have been identified as processes being involved in the pathoetiology of MG. Transcription factors such as CTCF, TAF1, and MYC as trans-regulatory mechanism for modulation of lncRNAs and genes, showing an important transcription factor–lncRNA–target gene network in the context MG [16]. Table 1 summarizes the role of lncRNAs in MG.
Table 1.
Role of lncRNAs in MG (PBMC: peripheral blood mononuclear cell, qRT-PCR: quantitative reverse transcription PCR, HC: healthy control, NC: negative control (cardiac surgery cases), MG-T: myasthenia gravis-related thymoma, QMGS: Quantitative Myasthenia Gravis Score).
3. miRNAs and MG
miRNAs are small regulatory molecules acting at post-transcriptional level to finely modulate the expression of genes. miRNAs can participate in the evolution of MG through different mechanisms. A system biology approach in the context of MG has led to construction of transcription factor/miRNA/gene network. Subsequent analyses have resulted in extraction of 5 genes, 3 transcription factors, and 13 miRNAs. Notably, MYC has been identified as the key transcription factor in MG. The identified genes and miRNAs were principally enriched in cancer- and infection-associated pathways. In addition, the composite feed-forward loop motif-specific subnetwork has shown the potential beneficial impact of estradiol, estramustine, raloxifene, and tamoxifen in treatment of MG [20].
An integrative bioinformatics approach and literature search has led to identification of 41 MG-associated signaling pathways and 105 medications that can influence these pathways. Notably, MG-associated miRNAs and drugs can affect key MG-associated pathways, including cytokine–cytokine receptor interaction. This approach has also shown that rituximab, adalimumab, sunitinib, and muromonab might influence MG course, potentiating these drugs as novel treatments for MG [21].
Expression profiling of samples obtained from orbicularis oculi muscle (OOM) and paralyzed extraocular muscle (EOM) of patients with ophthalmoplegic MG has shown similar expression profiles of transcripts among OOM and EOM samples. Ophthalmoplegic MG cases have exhibited downregulation of eight genes in OOM samples compared with controls. The mitochondrial transcription factor TFAM has been among these genes. Notably, numerous miRNAs known to be upregulated in EOM samples have been predicted to affect expression of a number of these genes [22].
Additionally, MG risk pathways such as T cell receptor and Toll-like receptor pathways as well as natural killer cell-mediated cytotoxicity have been shown to be targeted by several miRNAs. Notably, a number of miRSNPs “switches” have been found that affect miRNA regulation in the MG-associated pathways. These miRSNPs can affect gene expressions and pathway activities. An example of these SNPS is rs28457673 (miR-15/16/195/424/497 family), which affects IGF1R expression [23]. Another bioinformatics study has predicted the effects of 18 MG-associated miRNAs on expression of MAPK1, SMAD4, SMAD2, and BCL2 and their subsequent impact on cellular pathways associated with adherens, junctions, apoptosis, or cancer-related features. These important genes negatively regulate T cell differentiation [24].
Another miRNA profiling study has shown differential expression of 41 miRNAs among MG patients who respond to immunosuppressive treatments versus non-responders. Three miRNAs clustered on 14q32.31—namely, miR-323b-3p, miR-409-3p, and miR-485-3p have been validated to be expressed at lower levels in non-responder compared with responders, while miR-181d-5p and miR-340-3p have exhibited the opposite trend. miR-323b-3p, miR-409-3p, and miR-485-3p have been suggested as markers for the prediction of response to immunosuppressive treatment in MG. Five miRNAs have been predicted to be associated with immune functions and drug metabolism. In brief, miR-323b-3p, miR-409-3p, miR-485-3p, miR-181d-5p, and miR-340-3p expression profiles are correlated with therapeutic response in MG patients [25]. Another investigation has reported downregulation of miR-320a in MG patients compared with control subjects, parallel with upregulation of pro-inflammatory cytokines in these patients. MAPK1 has been identified as a direct target of miR-320a. miR-320a downregulation has led to upregulation of pro-inflammatory cytokines via increasing expression of COX-2. This process was regulated by ERK and NF-κB signaling pathways [26]. Table 2 shows the role of miRNAs in MG.
Table 2.
Role of miRNAs in MG (PBMC: peripheral blood mononuclear cell, qRT-PCR: quantitative reverse transcription PCR, HC: healthy control, NC: negative control (cardiac surgery cases), LOMG: late-onset myasthenia gravis, EOMG: early-onset myasthenia gravis, TAMG: thymoma-associated myasthenia gravis, MGH: myasthenia gravis patients with thymus hyperplasia, OMG: ocular myasthenia gravis, GMG: generalized myasthenia gravis, RTX: rituximab, QMGS: Quantitative Myasthenia Gravis Score).
4. Discussion
MG is an autoimmune disorder with multifactorial inheritance. Epigenetic factors such as regulatory non-coding RNAs have been found to affect pathogenesis of this disorder, possibly linking between environmental and genetic factors. LncRNAs can affect immune cells phenotypes, modulate balance between Th17 and Treg cells, and regulate expression of proinflammatory cytokines. miRNAs have been more investigated in the context of MG compared with lncRNAs. A number of lncRNAs that have been found to contribute to MG pathogenesis act as ceRNAs for miRNAs, further highlighting the impact of miRNAs in MG. Examples of lncRNA/miRNA/mRNA axes in participating in the pathogenesis of MG are SNHG16/let-7c-5p/IL-10 and MALAT-1/miR-338-3p/MSL2. In addition, high throughput studies have established some transcription factor/lncRNA/target gene networks in the context of MG, adding a layer of complexity in regulation of function of ncRNAs in this context.
Several of the lncRNAs and miRNAs that affect pathogenesis of MG converge on NF-κB and TNF signaling pathways. Moreover, expression profiles of these transcripts have been changed in response to immunomodulatory therapies, particularly corticosteroids.
A number of miRNAs have differential expression between different classes of MG, particularly those with and without thymoma. Moreover, the expression profile of some ncRNAs such as miR-106a-5p, miR-23b, miR-27a-3p, and IFNG-AS1 has been correlated with disease severity and QMG score, suggesting their participation in the pathoetiology of MG.
NcRNAs, particularly miRNAs, have the potential to be used as markers for the predication of response of MG patients to prescribed drugs and for the stratification of patients based on this issue to design patient-specific therapeutic regimens. Moreover, expression of these transcripts might be different during distinct stages of MG, potentiating these transcripts as biomarkers for differentiation of disease status. In spite of extensive research in this field, it is not clear how the expression profile of these transcripts can affect the course of disorder or define the muscle groups that are affected during disease course.
Due to the complex nature of participation of genetic factors in the pathogenesis of MG, high throughput studies are needed to find factors acting at upstream and downstream of lncRNAs and miRNAs. This type of study will reveal novel transcription factor/lncRNA/miRNA/mRNA axes with putative roles in the pathophysiology of MG. These molecular axes represent therapeutic targets for MG. Moreover, system biology approaches have potential for the discovery of novel drugs for the treatment of MG.
The impact of miRNAs on drug response has been suggested through both system biology and experimental studies, potentiating these transcripts as targets for therapeutic interventions. Taken together, miRNAs and lncRNAs partake in the pathoetiology of MG, disease course, and response to immunosuppressive treatments. Thus, these transcripts can be used as markers for prediction of these aspects.
5. Conclusions and Future Perspectives
As an autoimmune disorder, MG is associated with dysregulation of miRNAs and lncRNAs. However, the therapeutic implications of these transcripts in MG are not clear. The biomarker role of non-coding RNAs in MG has been investigated. Nonetheless, there is no clear evidence of whether the expression profile of these transcripts can determine disease course or involvement of certain groups of muscles. Future high throughput sequencing experiments should unravel differential expression of ncRNAs during different stages of MG.
Author Contributions
S.G.-F. wrote the draft and revised it. M.T. designed and supervised the study. T.A., R.J.K. and B.M.H. collected the data and desigend the tables. All authors have read and agreed to the published version of the manuscript.
Funding
Not applicable.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
Not applicable.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Gomez, A.M.; Broeck, J.V.D.; Vrolix, K.; Janssen, S.P.; Lemmens, M.A.M.; Van Der Esch, E.; Duimel, H.; Frederik, P.; Molenaar, P.C.; Martínez-Martínez, P.; et al. Antibody effector mechanisms in myasthenia gravis—Pathogenesis at the neuromuscular junction. Autoimmunity 2010, 43, 353–370. [Google Scholar] [CrossRef] [Scilit]
- Lindstrom, J.M.; Seybold, M.E.; Lennon, V.A.; Whittingham, S.; Duane, D.D. Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates, and diagnostic value. Neurology 1976, 26, 1054. [Google Scholar] [CrossRef] [Scilit]
- Hoch, W.; McConville, J.; Helms, S.; Newsom-Davis, J.; Melms, A.; Vincent, A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 2001, 7, 365–368. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pevzner, A.; Schoser, B.; Peters, K.; Cosma, N.-C.; Karakatsani, A.; Schalke, B.; Melms, A.; Kröger, S. Anti-LRP4 autoantibodies in AChR-and MuSK-antibody-negative myasthenia gravis. J. Neurol. 2012, 259, 427–435. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Avidan, N.; Le Panse, R.; Berrih-Aknin, S.; Miller, A. Genetic basis of myasthenia gravis—A comprehensive review. J. Autoimmun. 2014, 52, 146–153. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Melzer, N.; Ruck, T.; Fuhr, P.; Gold, R.; Hohlfeld, R.; Marx, A.; Melms, A.; Tackenberg, B.; Schalke, B.; Schneider-Gold, C.; et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: A supplement to the Guidelines of the German Neurological Society. J. Neurol. 2016, 263, 1473–1494. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zagoriti, Z.; Kambouris, M.E.; Patrinos, G.P.; Tzartos, S.J.; Poulas, K. Recent Advances in Genetic Predisposition of Myasthenia Gravis. BioMed Res. Int. 2013, 2013, 404053. [Google Scholar] [CrossRef] [Scilit]
- Meriggioli, M.N.; Sanders, D.B. Autoimmune myasthenia gravis: Emerging clinical and biological heterogeneity. Lancet Neurol. 2009, 8, 475–490. [Google Scholar] [CrossRef] [Scilit]
- Zhang, X.; Wang, W.; Zhu, W.; Dong, J.; Cheng, Y.; Yin, Z.; Shen, F. Mechanisms and Functions of Long Non-Coding RNAs at Multiple Regulatory Levels. Int. J. Mol. Sci. 2019, 20, 5573. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hu, B.; Niu, L.; Jiang, Z.; Xu, S.; Hu, Y.; Cao, K. LncRNA XLOC_003810 promotes T cell activation and inhibits PD-1/PD-L1 expression in patients with myasthenia gravis-related thymoma. Scand. J. Immunol. 2020, 92, e12886. [Google Scholar] [CrossRef] [Scilit]
- Niu, L.; Jiang, J.; Yin, Y.; Hu, B. LncRNA XLOC_003810 modulates thymic Th17/Treg balance in myasthenia gravis with thymoma. Clin. Exp. Pharmacol. Physiol. 2020, 47, 989–996. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wang, J.; Cao, Y.; Lu, X.; Wang, X.; Kong, X.; Bo, C.; Li, S.; Bai, M.; Jiao, Y.; Gao, H.; et al. Identification of the regulatory role of lncRNA SNHG16 in myasthenia gravis by constructing a competing endogenous RNA network. Mol. Ther.-Nucleic Acids 2020, 19, 1123–1133. [Google Scholar] [CrossRef] [Scilit]
- Luo, M.; Liu, X.; Meng, H.; Xu, L.; Li, Y.; Li, Z.; Liu, C.; Luo, Y.-B.; Hu, B.; Xue, Y.; et al. IFNA-AS1 regulates CD4 + T cell activation in myasthenia gravis though HLA-DRB1. Clin. Immunol. 2017, 183, 121–131. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kong, X.; Wang, J.; Cao, Y.; Zhang, H.; Lu, X.; Wang, Y.; Bo, C.; Wang, T.; Li, S.; Tian, K.; et al. The long noncoding RNA MALAT-1 functions as a competing endogenous RNA to regulate MSL2 expression by sponging miR-338-3p in myasthenia gravis. J. Cell. Biochem. 2019, 120, 5542–5550. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhang, F.; Liu, G.; Bu, Y.; Ma, X.; Hao, J. Expression profile of long noncoding RNAs and mRNAs in peripheral blood mononuclear cells from myasthenia gravis patients. J. Neuroimmunol. 2016, 299, 124–129. [Google Scholar] [CrossRef] [Scilit]
- Luo, Z.; Li, Y.; Liu, X.; Luo, M.; Xu, L.; Luo, Y.; Xiao, B.; Yang, H. Systems biology of myasthenia gravis, integration of aberrant lncRNA and mRNA expression changes. BMC Med. Genom. 2015, 8, 13. [Google Scholar] [CrossRef] [Scilit]
- Hong, Y.; Liang, X.; Gilhus, N.E. AChR antibodies show a complex interaction with human skeletal muscle cells in a transcriptomic study. Sci. Rep. 2020, 10, 11230. [Google Scholar] [CrossRef] [Scilit]
- Barzago, C.; Lum, J.; Cavalcante, P.; Srinivasan, K.G.; Faggiani, E.; Camera, G.; Bonanno, S.; Andreetta, F.; Antozzi, C.; Baggi, F.; et al. A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients. Immunobiology 2016, 221, 1227–1236. [Google Scholar] [CrossRef] [Scilit]
- Lu, W.; Lu, Y.; Wang, C.; Chen, T. Expression profiling and bioinformatics analysis of exosomal long noncoding RNAs in patients with myasthenia gravis by RNA sequencing. J. Clin. Lab. Anal. 2021, 35, e23722. [Google Scholar] [CrossRef] [Scilit]
- Bo, C.; Zhang, H.; Cao, Y.; Lu, X.; Zhang, C.; Li, S.; Kong, X.; Zhang, X.; Bai, M.; Tian, K.; et al. Construction of a TF-miRNA-gene feed-forward loop network predicts biomarkers and potential drugs for myasthenia gravis. Sci. Rep. 2021, 11, 2416. [Google Scholar] [CrossRef] [Scilit]
- Cao, Y.; Lu, X.; Wang, J.; Zhang, H.; Liu, Z.; Xu, S.; Wang, T.; Ning, S.; Xiao, B.; Wang, L. Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis. Int. J. Mol. Med. 2017, 39, 268–278. [Google Scholar] [CrossRef] [Scilit]
- Europa, T.A.; Nel, M.; Heckmann, J.M. Gene expression profiling of orbital muscles in treatment-resistant ophthalmoplegic myasthenia gravis. Orphanet J. Rare Dis. 2020, 15, 346. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Yang, L.; Wang, J.; Sun, X.; Cao, Y.; Ning, S.; Zhang, H.; Chen, L.; Li, R.; Tian, Q.; Wang, L.; et al. Identifying a Polymorphic ‘Switch’ That Influences miRNAs’ Regulation of a Myasthenia Gravis Risk Pathway. PLoS ONE 2014, 9, e104827. [Google Scholar] [CrossRef] [Scilit]
- Qian, K.; Xu, J.-X.; Deng, Y.; Peng, H.; Peng, J.; Ou, C.-M.; Liu, Z.; Jiang, L.-H.; Tai, Y.-H. Signaling pathways of genetic variants and miRNAs in the pathogenesis of myasthenia gravis. Gland. Surg. 2020, 9, 1933–1944. [Google Scholar] [CrossRef] [Scilit]
- Cavalcante, P.; Mizrachi, T.; Barzago, C.; Scandiffio, L.; Bortone, F.; Bonanno, S.; Frangiamore, R.; Mantegazza, R.; Bernasconi, P.; Brenner, T.; et al. MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicine. Pharmacol. Res. 2019, 148, 104388. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Cheng, Z.; Qiu, S.; Jiang, L.; Zhang, A.; Bao, W.; Liu, P.; Liu, J. MiR-320a is Downregulated in Patients with Myasthenia Gravis and Modulates Inflammatory Cytokines Production by Targeting Mitogen-activated Protein Kinase 1. J. Clin. Immunol. 2012, 33, 567–576. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Cao, Y.; Wang, J.; Zhang, H.; Tian, Q.; Chen, L.; Ning, S.; Liu, P.; Sun, X.; Lu, X.; Song, C. Detecting key genes regulated by miRNAs in dysfunctional crosstalk pathway of myasthenia gravis. BioMed Res. Int. 2015, 2015, 724715. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sengupta, M.; Wang, B.-D.; Lee, N.H.; Marx, A.; Kusner, L.L.; Kaminski, H.J. MicroRNA and mRNA expression associated with ectopic germinal centers in thymus of myasthenia gravis. PLoS ONE 2018, 13, e0205464. [Google Scholar] [CrossRef] [Scilit]
- Cron, M.A.; Maillard, S.; Delisle, F.; Samson, N.; Truffault, F.; Foti, M.; Fadel, E.; Guihaire, J.; Berrih-Aknin, S.; Le Panse, R. Analysis of microRNA expression in the thymus of Myasthenia Gravis patients opens new research avenues. Autoimmun. Rev. 2018, 17, 588–600. [Google Scholar] [CrossRef] [Scilit]
- Jiang, L.; Cheng, Z.; Qiu, S.; Que, Z.; Bao, W.; Jiang, C.; Zou, F.; Liu, P.; Liu, J. Altered let-7 expression in Myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells. Int. Immunopharmacol. 2012, 14, 217–223. [Google Scholar] [CrossRef] [Scilit]
- Li, J.; Qiu, D.; Chen, Z.; Du, W.; Liu, J.; Mo, X. Altered expression of miR-125a-5p in thymoma-associated myasthenia gravis and its down-regulation of foxp3 expression in Jurkat cells. Immunol. Lett. 2016, 172, 47–55. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Li, J.; Qiu, D.; Chen, Z.; Du, W.; Liu, J.; Mo, X. miR-548k regulates CXCL13 expression in myasthenia gravis patients with thymic hyperplasia and in Jurkat cells. J. Neuroimmunol. 2018, 320, 125–132. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Nogales-Gadea, G.; Ramos-Fransi, A.; Suárez-Calvet, X.; Navas, M.; Rojas-García, R.; Mosquera, J.L.; Diaz-Manera, J.; Querol, L.; Gallardo, E.; Illa, I. Analysis of Serum miRNA Profiles of Myasthenia Gravis Patients. PLoS ONE 2014, 9, e91927. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wang, J.; Zheng, S.; Xin, N.; Dou, C.; Fu, L.; Zhang, X.; Chen, J.; Zhang, Y.; Geng, D.; Xiao, C. Identification of Novel MicroRNA Signatures Linked to Experimental Autoimmune Myasthenia Gravis Pathogenesis: Down-Regulated miR-145 Promotes Pathogenetic Th17 Cell Response. J. Neuroimmune Pharmacol. 2013, 8, 1287–1302. [Google Scholar] [CrossRef] [Scilit]
- Tan, Y.; Zhu, L.; Cui, L.; Guan, Y. Differential Expression of miRNA in the Peripheral Blood Mononuclear Cells in Myasthenia Gravis with Muscle-Specific Receptor Tyrosine Kinase Antibodies. Crit. Rev. Eukaryot. Gene Expr. 2021, 31, 1–15. [Google Scholar] [CrossRef] [Scilit]
- Punga, T.; Bartoccioni, E.; Lewandowska, M.; Damato, V.; Evoli, A.; Punga, A.R. Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis. J. Neuroimmunol. 2016, 292, 21–26. [Google Scholar] [CrossRef] [Scilit]
- Sabre, L.; Guptill, J.T.; Russo, M.; Juel, V.C.; Massey, J.M.; Howard, J.F.; Hobson-Webb, L.D.; Punga, A.R. Circulating microRNA plasma profile in MuSK plus myasthenia gravis. J. Neuroimmunol. 2018, 325, 87–91. [Google Scholar] [CrossRef] [Scilit]
- Punga, T.; Panse, R.L.; Andersson, M.; Truffault, F.; Berrih-Aknin, S.; Punga, A.R. Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker. Ann. Clin. Transl. Neurol. 2014, 1, 49–58. [Google Scholar] [CrossRef] [Scilit]
- Sabre, L.; Maddison, P.; Sadalage, G.; Ambrose, P.A.; Punga, A.R. Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis. J. Neuroimmunol. 2018, 321, 164–170. [Google Scholar] [CrossRef] [Scilit]
- Sabre, L.; Maddison, P.; Wong, S.H.; Sadalage, G.; Ambrose, P.A.; Plant, G.T.; Punga, A.R. miR-30e-5p as predictor of generalization in ocular myasthenia gravis. Ann. Clin. Transl. Neurol. 2019, 6, 243–251. [Google Scholar] [CrossRef] [Scilit]
- Jiang, C.; Liu, P.; Zhang, J.; Bao, W.; Qiu, S.; Liang, Y.; Jiang, L. Clinical Study of Effects of Jian Ji Ning, a Chinese Herbal Medicine Compound Preparation, in Treating Patients with Myasthenia Gravis via the Regulation of Differential MicroRNAs Expression in Serum. Evid. -Based Complement. Altern. Med. 2014, 2014, 518942. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Xu, H.Y.; Bao, Z.; Liang, D.; Li, M.; Wei, M.; Ge, X.; Liu, J.; Li, J. Plasma exosomal miR-106a-5p expression in myasthenia gravis. Muscle Nerve 2020, 61, 401–407. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Liu, H.; Shi, L.; Liu, T.; Zhang, M.; Guo, Y.; Song, C.; Song, D. miR-15b is Downregulated in Myasthenia Gravis Patients and Directly Regulates the Expression of Interleukin-15 (IL-15) in Experimental Myasthenia Gravis Mice. Med. Sci. Monit. 2015, 21, 1774–1780. [Google Scholar] [CrossRef] [Scilit]
- Liu, X.-F.; Wang, R.-Q.; Hu, B.; Luo, M.-C.; Zeng, Q.-M.; Zhou, H.; Huang, K.; Dong, X.-H.; Luo, Y.-B.; Luo, Z.-H.; et al. MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10. Clin. Immunol. 2016, 164, 106–113. [Google Scholar] [CrossRef] [Scilit]
- Wang, Z.; Chen, Y.; Xu, S.; Yang, Y.; Wei, D.; Wang, W.; Huang, X. Aberrant decrease of microRNA19b regulates TSLP expression and contributes to Th17 cells development in myasthenia gravis related thymomas. J. Neuroimmunol. 2015, 288, 34–39. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- ChunJie, N.; Huijuan, N.; Zhao, Y.; Jianzhao, W.; Xiaojian, Z. Disease-specific signature of serum miR-20b and its targets IL-8 and IL-25, in myasthenia gravis patients. Eur. Cytokine Netw. 2015, 26, 61–66. [Google Scholar] [CrossRef] [Scilit]
- Huang, P.; He, X.-Y.; Xu, M. Expression and Significance of MicroRNA-126 and MicroRNA-21 in Peripheral Blood Mononuclear Cells in Patients with Myasthenia Gravis. Neuroimmunomodulation 2021, 1–8. [Google Scholar] [CrossRef] [Scilit]
- Zhou, X.; Wang, J.; Zhang, H.; Wang, L. Altered expression and clinical significance of plasma circulating microRNA-23b in patients with myasthnia gravis. Chin. J. Neurol. 2017, 50, 213–217. [Google Scholar]
- Li, Q.; Wang, L.; Wang, J.; Zhang, H.; Shan, X.; Kong, X. Altered expression of microRNA-27a-3p in the thymus tissue of patients with myasthenia gravis. Chin. J. Neurol. 2016, 49, 302–306. [Google Scholar]
- Cron, M.A.; Payet, C.A.; Fayet, O.-M.; Maillard, S.; Truffault, F.; Fadel, E.; Guihaire, J.; Berrih-Aknin, S.; Liston, A.; Panse, R.L. Decreased expression of miR-29 family associated with autoimmune myasthenia gravis. J. Neuroinflamm. 2020, 17, 294. [Google Scholar] [CrossRef] [Scilit]
- Lai, X.; Bi, Z.; Yang, X.; Hu, R.; Wang, L.; Jin, M.; Li, L.; Bu, B. Upregulation of circ-FBL promotes myogenic proliferation in myasthenia gravis by regulation of miR-133/PAX7. Cell Biol. Int. 2021, 45, 2287–2293. [Google Scholar] [CrossRef] [Scilit]
- Bortone, F.; Scandiffio, L.; Marcuzzo, S.; Bonanno, S.; Frangiamore, R.; Motta, T.; Antozzi, C.; Mantegazza, R.; Cavalcante, P.; Bernasconi, P. miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids. Front. Immunol. 2020, 11, 142. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Yan, M.; Fu, Y.; Rao, H.; Zhou, H.; Liang, X. Expression and Clinical Significance of miR-146a and Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF6) in Myasthenia Gravis Patient Serum. BioMed Res. Int. 2021, 2021, 5573469. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Huang, P.; He, X.-Y.; Xu, M. The Expression of miRNA-146a in Peripheral Blood Mononuclear Cells of Patients with Myasthenia Gravis and Its Bioinformatics Analysis. J. Biomater. Tissue Eng. 2019, 9, 1670–1675. [Google Scholar] [CrossRef] [Scilit]
- Lu, J.; Yan, M.; Wang, Y.; Zhang, J.; Yang, H.; Tian, F.-F.; Zhou, W.; Zhang, N.; Li, J. Altered expression of miR-146a in myasthenia gravis. Neurosci. Lett. 2013, 555, 85–90. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhong, H.; Lu, J.; Jing, S.; Xi, J.; Yan, C.; Song, J.; Luo, S.; Zhao, C. Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients. J. Neuroimmunol. 2020, 348, 577383. [Google Scholar] [CrossRef] [Scilit]
- Ao, W.; Tian, C.; He, X.; Hu, Y.; Wang, W.; Liu, Y. Upregulation of miR150-5p in generalized myasthenia gravis patients is associated with decreased serum levels of IL-17 and increased serum levels of IL-10. Biomed. Pap. 2020, 164, 57–62. [Google Scholar] [CrossRef] [Scilit]
- Cron, M.A.; Maillard, S.; Truffault, F.; Gualeni, A.V.; Gloghini, A.; Fadel, E.; Guihaire, J.; Behin, A.; Berrih-Aknin, S.; Le Panse, R. Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis. Front. Immunol. 2019, 10, 539. [Google Scholar] [CrossRef] [Scilit]
- Molin, C.J.; Sabre, L.; Weis, C.-A.; Punga, T.; Punga, A.R. Thymectomy lowers the myasthenia gravis biomarker miR-150-5p. Neurol. Neuroimmunol. Neuroinflamm. 2018, 5, e450. [Google Scholar] [CrossRef] [Scilit]
- Punga, A.R.; Andersson, M.; Alimohammadi, M.; Punga, T. Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients. J. Neurol. Sci. 2015, 356, 90–96. [Google Scholar] [CrossRef] [Scilit]
- Westerberg, E.; Molin, C.J.; Lindblad, I.; Emtner, M.; Punga, A.R. Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance-based measures: A pilot study. Muscle Nerve 2017, 56, 207–214. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhou, Y.; Yan, C.; Gu, X.; Zhou, L.; Lu, J.; Zhu, W.; Huan, X.; Luo, S.; Zhong, H.; Lin, J. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody. Muscle Nerve 2021, 63, 824–830. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Chen, X.; Chen, Y.; Wang, Y.; Yan, M.; Zhang, J.; Liu, Q.; Yang, H.; Li, J. Role of miR-155 in myasthenia gravis and effect of dexamethasone on miR-155. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2012, 37, 777–782. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.-Z.; Tian, F.-F.; Yan, M.; Zhang, J.-M.; Liu, Q.; Lu, J.-Y.; Zhou, W.-B.; Yang, H.; Li, J. Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis. Clin. Exp. Immunol. 2014, 176, 207–221. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhang, Y.; Guo, M.; Xin, N.; Shao, Z.; Zhang, X.; Zhang, Y.; Chen, J.; Zheng, S.; Fu, L.; Wang, Y. Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis. Clin. Exp. Med. 2016, 16, 413–421. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lu, H.; Wang, H.; Sun, P.; Wang, J.; Li, S.; Xu, T. MiR-522-3p inhibits proliferation and activation by regulating the expression of SLC31A1 in T cells. Cytotechnology 2021, 73, 483–496. [Google Scholar] [CrossRef] [Scilit]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).